Gambling, Resorts & Casinos
Compare Stocks
4 / 10Stock Comparison
SBET vs PENN vs CZR vs GENI
Revenue, margins, valuation, and 5-year total return — side by side.
Gambling, Resorts & Casinos
Gambling, Resorts & Casinos
Internet Content & Information
SBET vs PENN vs CZR vs GENI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Gambling, Resorts & Casinos | Gambling, Resorts & Casinos | Gambling, Resorts & Casinos | Internet Content & Information |
| Market Cap | $1.47B | $2.24B | $5.66B | $1.17B |
| Revenue (TTM) | $28M | $6.96B | $11.56B | $669M |
| Net Income (TTM) | $-735M | $-843M | $-485M | $-112M |
| Gross Margin | 93.2% | 30.6% | 43.9% | 22.9% |
| Operating Margin | -20.0% | -7.9% | 17.8% | -18.1% |
| Forward P/E | 6.1x | 22.8x | — | 52.4x |
| Total Debt | $0.00 | $8.38B | $26.34B | $30M |
| Cash & Equiv. | $29M | $687M | $887M | $281M |
SBET vs PENN vs CZR vs GENI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| SharpLink Gaming Lt… (SBET) | 100 | 2.7 | -97.3% |
| PENN Entertainment,… (PENN) | 100 | 31.0 | -69.0% |
| Caesars Entertainme… (CZR) | 100 | 62.6 | -37.4% |
| Genius Sports Limit… (GENI) | 100 | 43.8 | -56.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBET vs PENN vs CZR vs GENI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SBET carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 6.7%, EPS growth 53.7%, 3Y rev CAGR 100.3%
- 6.7% revenue growth vs CZR's 2.1%
- Lower P/E (6.1x vs 52.4x)
- +127.8% vs GENI's -53.1%
PENN plays a supporting role in this comparison — it may shine differently against other peers.
CZR is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 302.6% 10Y total return vs PENN's 11.9%
- Lower volatility, beta 1.27, current ratio 0.80x
- Beta 1.27, current ratio 0.80x
- -4.2% margin vs SBET's -26.2%
GENI is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.50
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.7% revenue growth vs CZR's 2.1% | |
| Value | Lower P/E (6.1x vs 52.4x) | |
| Quality / Margins | -4.2% margin vs SBET's -26.2% | |
| Stability / Safety | Beta 1.27 vs SBET's 3.41 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +127.8% vs GENI's -53.1% | |
| Efficiency (ROA) | -1.5% ROA vs SBET's -49.3%, ROIC 5.4% vs -35.2% |
SBET vs PENN vs CZR vs GENI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SBET vs PENN vs CZR vs GENI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CZR leads in 4 of 6 categories
SBET leads 1 • GENI leads 1 • PENN leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
SBET leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CZR is the larger business by revenue, generating $11.6B annually — 412.1x SBET's $28M. CZR is the more profitable business, keeping -4.2% of every revenue dollar as net income compared to SBET's -26.2%. On growth, SBET holds the edge at +18.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $28M | $7.0B | $11.6B | $669M |
| EBITDAEarnings before interest/tax | -$561M | -$105M | $3.5B | -$50M |
| Net IncomeAfter-tax profit | -$735M | -$843M | -$485M | -$112M |
| Free Cash FlowCash after capex | -$18M | -$169M | $538M | $37M |
| Gross MarginGross profit ÷ Revenue | +93.2% | +30.6% | +43.9% | +22.9% |
| Operating MarginEBIT ÷ Revenue | -20.0% | -7.9% | +17.8% | -18.1% |
| Net MarginNet income ÷ Revenue | -26.2% | -12.1% | -4.2% | -16.7% |
| FCF MarginFCF ÷ Revenue | -65.1% | -2.4% | +4.7% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.2% | +8.2% | +2.7% | +37.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +94.3% | +37.5% | +11.1% | +33.8% |
Valuation Metrics
CZR leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CZR's 8.9x EV/EBITDA is more attractive than PENN's 13.8x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.5B | $2.2B | $5.7B | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $9.9B | $31.1B | $924M |
| Trailing P/EPrice ÷ TTM EPS | -1.01x | -2.88x | -11.48x | -10.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.10x | 22.79x | — | 52.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.81x | 8.90x | — |
| Price / SalesMarket cap ÷ Revenue | 52.23x | 0.32x | 0.49x | 1.75x |
| Price / BookPrice ÷ Book value/share | 0.61x | 1.33x | 1.57x | 1.68x |
| Price / FCFMarket cap ÷ FCF | — | — | 10.88x | 18.18x |
Profitability & Efficiency
CZR leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CZR delivers a -12.6% return on equity — every $100 of shareholder capital generates $-13 in annual profit, vs $-49 for SBET. GENI carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to CZR's 7.15x. On the Piotroski fundamental quality scale (0–9), PENN scores 5/9 vs GENI's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -49.5% | -34.7% | -12.6% | -15.5% |
| ROA (TTM)Return on assets | -49.3% | -5.7% | -1.5% | -11.1% |
| ROICReturn on invested capital | -35.2% | +1.8% | +5.4% | -16.6% |
| ROCEReturn on capital employed | -46.3% | +2.0% | +7.0% | -15.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 5 | 3 |
| Debt / EquityFinancial leverage | — | 4.58x | 7.15x | 0.04x |
| Net DebtTotal debt minus cash | -$29M | $7.7B | $25.5B | -$250M |
| Cash & Equiv.Liquid assets | $29M | $687M | $887M | $281M |
| Total DebtShort + long-term debt | $0 | $8.4B | $26.3B | $30M |
| Interest CoverageEBIT ÷ Interest expense | — | -1.02x | 0.90x | -136.57x |
Total Returns (Dividends Reinvested)
CZR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CZR five years ago would be worth $2,627 today (with dividends reinvested), compared to $112 for SBET. Over the past 12 months, SBET leads with a +127.8% total return vs GENI's -53.1%. The 3-year compound annual growth rate (CAGR) favors GENI at 5.5% vs SBET's -42.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -23.1% | +12.9% | +17.9% | -55.8% |
| 1-Year ReturnPast 12 months | +127.8% | +6.7% | +2.5% | -53.1% |
| 3-Year ReturnCumulative with dividends | -81.4% | -35.3% | -38.6% | +17.4% |
| 5-Year ReturnCumulative with dividends | -98.9% | -80.6% | -73.7% | -74.6% |
| 10-Year ReturnCumulative with dividends | -98.4% | +11.9% | +302.6% | -52.4% |
| CAGR (3Y)Annualised 3-year return | -42.9% | -13.5% | -15.0% | +5.5% |
Risk & Volatility
CZR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CZR is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than SBET's 3.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CZR currently trades 88.0% from its 52-week high vs SBET's 6.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.41x | 1.31x | 1.24x | 1.39x |
| 52-Week HighHighest price in past year | $124.12 | $20.61 | $31.58 | $13.73 |
| 52-Week LowLowest price in past year | $2.41 | $11.65 | $17.95 | $3.83 |
| % of 52W HighCurrent price vs 52-week peak | +6.0% | +81.4% | +88.0% | +34.7% |
| RSI (14)Momentum oscillator 0–100 | 58.6 | 55.1 | 54.5 | 45.3 |
| Avg Volume (50D)Average daily shares traded | 6.9M | 4.4M | 4.6M | 5.6M |
Analyst Outlook
GENI leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SBET as "Buy", PENN as "Buy", CZR as "Buy", GENI as "Buy". Consensus price targets imply 153.9% upside for GENI (target: $12) vs 10.0% for CZR (target: $31).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $20.29 | $30.57 | $12.10 |
| # AnalystsCovering analysts | 3 | 47 | 30 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | 0 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.2% | +15.8% | +4.0% | 0.0% |
CZR leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). SBET leads in 1 (Income & Cash Flow).
SBET vs PENN vs CZR vs GENI: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SBET or PENN or CZR or GENI a better buy right now?
For growth investors, SharpLink Gaming Ltd.
(SBET) is the stronger pick with 666. 0% revenue growth year-over-year, versus 2. 1% for Caesars Entertainment, Inc. (CZR). Analysts rate SharpLink Gaming Ltd. (SBET) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SBET or PENN or CZR or GENI?
Over the past 5 years, Caesars Entertainment, Inc.
(CZR) delivered a total return of -73. 7%, compared to -98. 9% for SharpLink Gaming Ltd. (SBET). Over 10 years, the gap is even starker: CZR returned +306. 4% versus SBET's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SBET or PENN or CZR or GENI?
By beta (market sensitivity over 5 years), Caesars Entertainment, Inc.
(CZR) is the lower-risk stock at 1. 24β versus SharpLink Gaming Ltd. 's 3. 41β — meaning SBET is approximately 176% more volatile than CZR relative to the S&P 500. On balance sheet safety, Genius Sports Limited (GENI) carries a lower debt/equity ratio of 4% versus 7% for Caesars Entertainment, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SBET or PENN or CZR or GENI?
By revenue growth (latest reported year), SharpLink Gaming Ltd.
(SBET) is pulling ahead at 666. 0% versus 2. 1% for Caesars Entertainment, Inc. (CZR). On earnings-per-share growth, the picture is similar: SharpLink Gaming Ltd. grew EPS 53. 7% year-over-year, compared to -184. 4% for PENN Entertainment, Inc.. Over a 3-year CAGR, SBET leads at 100. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SBET or PENN or CZR or GENI?
Caesars Entertainment, Inc.
(CZR) is the more profitable company, earning -4. 4% net margin versus -26. 2% for SharpLink Gaming Ltd. — meaning it keeps -4. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CZR leads at 18. 1% versus -1999. 5% for SBET. At the gross margin level — before operating expenses — SBET leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SBET or PENN or CZR or GENI more undervalued right now?
On forward earnings alone, SharpLink Gaming Ltd.
(SBET) trades at 6. 1x forward P/E versus 52. 4x for Genius Sports Limited — 46. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GENI: 153. 9% to $12. 10.
07Which pays a better dividend — SBET or PENN or CZR or GENI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SBET or PENN or CZR or GENI better for a retirement portfolio?
For long-horizon retirement investors, Caesars Entertainment, Inc.
(CZR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24), +306. 4% 10Y return). SharpLink Gaming Ltd. (SBET) carries a higher beta of 3. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CZR: +306. 4%, SBET: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SBET and PENN and CZR and GENI?
These companies operate in different sectors (SBET (Consumer Cyclical) and PENN (Consumer Cyclical) and CZR (Consumer Cyclical) and GENI (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SBET is a small-cap high-growth stock; PENN is a small-cap quality compounder stock; CZR is a small-cap quality compounder stock; GENI is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 18%
- Gross Margin > 13%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.